Economic Burden of NAFLD

NCT ID: NCT05035043

Last Updated: 2025-12-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

73 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-01

Study Completion Date

2024-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine the economic burden of NAFLD (Non-Alcoholic-Fatty-Liver Disease) patients in Belgium, Flanders by means of a bottom-up approach.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Alcoholic Fatty Liver Disease NAFLD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NAFLD patients

Non-Alcoholic Fatty Liver Disease patients

Group Type EXPERIMENTAL

Determination of the economic burden NAFLD patients

Intervention Type OTHER

Determination of the economic burden NAFLD patients (Healthcare costs, patient costs, burden of disease

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Determination of the economic burden NAFLD patients

Determination of the economic burden NAFLD patients (Healthcare costs, patient costs, burden of disease

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* having NAFLD as was diagnosed by FibroScan®,
* 18 years or older
* BMI ≥ 25 kg/m²

Exclusion Criteria

* unable to give informed consent
* \>70 years
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hasselt University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Geert Robaeys

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Geert Robaeys, prof. dr.

Role: PRINCIPAL_INVESTIGATOR

Hasselt University

Leen Heyens

Role: STUDY_CHAIR

Hasselt University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hasselt University

Hasselt, , Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EB-NAFLD-DGP-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

NAFLD Primary Care
NCT04918732 RECRUITING NA
LITMUS Imaging Study
NCT05479721 ACTIVE_NOT_RECRUITING
NASH and Coronary Disease
NCT03819283 UNKNOWN NA
Prevalence of NAFLD in T1DM Patients
NCT06445361 RECRUITING NA